Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$130.67 USD

130.67
1,327,706

+2.92 (2.29%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $130.73 +0.06 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: General Electric, Ford, 3M, Vir and Biogen

The Zacks Analyst Blog Highlights: General Electric, Ford, 3M, Vir and Biogen

Payal Jalan headshot

Diverse Companies Join Forces to Fight Coronavirus Menace

Nervousness related to the coronavirus outbreak is visible across the economies worldwide. Amid the pandemic, many corporates have come together to help contain the outbreak.

Zacks Equity Research

Biotech Stocks Accelerate Efforts for Coronavirus Treatments

Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.

Zacks Equity Research

AbbVie's Venclexta Combo Meets Endpoints in Leukemia Study

AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with azacitidine, achieves statistically significant improvement in overall survival and composite complete remission rate in treatment-naive AML patients.

Zacks Equity Research

J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.

Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.

Zacks Equity Research

Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Zacks Equity Research

Regeneron Up on Identification of Antibodies for Coronavirus

Regeneron (REGN) announces identification of antibodies from its VelocImmune mice for the treatment of coronavirus.

Zacks Equity Research

Gilead Up as Remdesivir Shows Promise in Treating Coronavirus

Gilead (GILD) leads the race of companies developing treatments for coronavirus with experimental candidate, remdesivir, showing promise.

Kaibalya Pravo Dey headshot

Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up

While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.

Kinjel Shah headshot

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

Ekta Bagri headshot

Biotech Sector in Focus as Coronavirus Spreads Panic

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon, IBM, Biogen, Newmont and Berkshire Hathaway

The Zacks Analyst Blog Highlights: Amazon, IBM, Biogen, Newmont and Berkshire Hathaway

Mark Vickery headshot

Top Analyst Reports for Amazon, IBM & Biogen

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), International Business Machines Corporation (IBM) and Biogen Inc. (BIIB).

Zacks Equity Research

J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe

Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio

Zacks Equity Research

Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More

The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.

Zacks Equity Research

AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study

AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.

Zacks Equity Research

Zacks Market Edge Highlights: Tesla, Micron, Biogen, GameStop and Maxar Technologies

Zacks Market Edge Highlights: Tesla, Micron, Biogen, GameStop and Maxar Technologies

Tracey Ryniec headshot

Stocks the Pros Loved Heading into 2020

As stocks hit new all-time highs to finish 2019, the professional money managers were busy positioning their portfolios for 2020. What were they buying, and selling, heading into the new year?

Kevin Cook headshot

Bull of the Day: Guardant Health (GH)

Cancer diagnostics provider who delivered 181% revenue growth and 18,500 tests to patients and labs partners with Amgen

Sanghamitra Saha headshot

Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas

Warren Buffett took positions in Biogen and Kroger. Investors who want to follow Buffett's picking of these two value stocks can also play these ETFs as well.

Zacks Equity Research

Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4

Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.

Sweta Jaiswal, FRM headshot

Can Biotech ETFs Gain on Mixed Q4 Earnings Results?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.

Zacks Equity Research

Western Union (WU) Q4 Earnings and Revenues Lag Estimates

Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VAREX IMAGING (VREX) Q1 Earnings Miss Estimates

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Diodes (DIOD) Q4 Earnings and Revenues Top Estimates

Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?